SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: cherry grove who wrote (3522)1/4/1998 1:40:00 PM
From: billkirn  Read Replies (2) of 6136
 
Cherry: I think we all have been hit pretty hard. Our enthusiasm got the best of us last sept/oct. I hope you still own Agouron as I feel very confident it will return to new highs, and it might take the entire year. I especially like the investment environment unfolding for 1998. Profits are not expected to increase very much for many companies so on a relative basis, Agouron should look very attractive.
With AG3340 emerging as a real cancer and arthritis inhibitor, Viracept contining to gain market share, increasing the earnings picture, and with the potential for Agouron to establish additional partnerships, it should be a good fundamental year and the stock price should reflect this over the next 12 months.

Good Luck, and hang in there.

Bill Kirn
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News